Adalimumab medium‐term dosing strategy in moderate‐to‐severe hidradenitis suppurativa: integrated results from the phase III randomized placebo‐controlled PIONEER trials

BACKGROUND: Weekly adalimumab (Humira(®)) is approved for the treatment of hidradenitis suppurativa (HS) based on the 12‐week placebo‐controlled periods of the two phase III PIONEER trials. OBJECTIVES: Using PIONEER integrated trial results, we aimed to evaluate the optimal medium‐term adalimumab ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Jemec, G.B.E., Okun, M.M., Forman, S.B., Gulliver, W.P.F., Prens, E.P., Mrowietz, U., Armstrong, A.W., Geng, Z., Gu, Y., Williams, D.A., Teixeira, H.D., Kimball, A.B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899827/
https://www.ncbi.nlm.nih.gov/pubmed/30916379
http://dx.doi.org/10.1111/bjd.17919

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899827/
https://www.ncbi.nlm.nih.gov/pubmed/30916379
http://dx.doi.org/10.1111/bjd.17919

Ejemplares similares